Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study
- Sponsor
- Eye & ENT Hospital of Fudan University
- Study ID
- NCT07652489
- Status
- Recruiting
Conditions
- Adenoid Cystic Carcinoma
- Sinonasal Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Surgery — PROCEDUREPostoperative Radiotherapy
Study Details
This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity/sinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.
Key Dates
- First listed
- Jun 17, 2026
- Start date
- Jun 1, 2026
- Status verified
- Jun 2026
- Primary completion
- Jun 1, 2031
- Completion
- Jun 1, 2031
Study Design
- Enrollment
- 70 participants (estimated)
Arms
- Arm: T4 Sinonasal Adenoid Cystic Carcinoma: Surgery plus Postoperative RadiotherapyThis single cohort includes patients with previously untreated T4 stage sinonasal adenoid cystic carcinoma (T4a or T4b, any N, M0 or M1 with stable limited lung metastases). All participants receive standard treatment as per routine clinical practice: radical surgery (aiming for R0/R1 resection, via endoscopic, open, or combined approach) followed by postoperative intensity-modulated radiotherapy (IMRT) starting within 4-6 weeks after surgery. No experimental intervention is assigned. The cohort is followed prospectively for 3 years to assess progression-free survival, overall survival, local control, distant metastasis, treatment-related complications, and quality of life.
Primary Outcome Measure
3-Year Progression-Free Survival [ Time Frame: Up to 3 years after enrollment ]
Central Contacts
- Quan Liu, MD+86 15001959681
- Wanpeng Li, MD+86 13262856870
Related Studies
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Prospective Sinonasal Cancer Multi-institution StudyRecruiting · Mayo Clinic · Rochester, Minnesota
- Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR TrialRecruiting · Dana-Farber Cancer Institute · San Francisco, California
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPHASE1/PHASE2 · Recruiting · Day One Biopharmaceuticals, Inc. · Phoenix, Arizona